Skip to main content

Broadly neutralizing antibodies abrogate established hepatitis C virus infection

Author(s): de Jong, YP; Dorner, M; Mommersteeg, MC; Xiao, JW; Balazs, AB; et al

Download
To refer to this page use: http://arks.princeton.edu/ark:/88435/pr1pv6b683
Full metadata record
DC FieldValueLanguage
dc.contributor.authorde Jong, YP-
dc.contributor.authorDorner, M-
dc.contributor.authorMommersteeg, MC-
dc.contributor.authorXiao, JW-
dc.contributor.authorBalazs, AB-
dc.contributor.authorRobbins, JB-
dc.contributor.authorWiner, BY-
dc.contributor.authorGerges, S-
dc.contributor.authorVega, K-
dc.contributor.authorLabitt, RN-
dc.contributor.authorDonovan, BM-
dc.contributor.authorGiang, E-
dc.contributor.authorKrishnan, A-
dc.contributor.authorChiriboga, L-
dc.contributor.authorCharlton, MR-
dc.contributor.authorBurton, DR-
dc.contributor.authorBaltimore, D-
dc.contributor.authorLaw, M-
dc.contributor.authorRice, CM-
dc.contributor.authorPloss, A-
dc.date.accessioned2023-12-11T17:50:11Z-
dc.date.available2023-12-11T17:50:11Z-
dc.date.issued2014-09-17en_US
dc.identifier.citationde Jong, YP, Dorner, M, Mommersteeg, MC, Xiao, JW, Balazs, AB, Robbins, JB, Winer, BY, Gerges, S, Vega, K, Labitt, RN, Donovan, BM, Giang, E, Krishnan, A, Chiriboga, L, Charlton, MR, Burton, DR, Baltimore, D, Law, M, Rice, CM, Ploss, A. (2014). Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Science Translational Medicine, 6 (254), 254ra129 - 254ra129. doi:10.1126/scitranslmed.3009512en_US
dc.identifier.issn1946-6234-
dc.identifier.urihttp://arks.princeton.edu/ark:/88435/pr1pv6b683-
dc.description.abstractHepatitis C virus (HCV) establishes a chronic infection in the majority of exposed individuals and can cause cirrhosis and hepatocellular carcinoma. The role of antibodies directed against HCV in disease progression is poorly understood. Neutralizing antibodies (nAbs) can prevent HCV infection in vitro and in animal models. However, the effects of nAbs on an established HCV infection are unclear. Here, we demonstrate that three broadly nAbs, AR3A, AR3B and AR4A, delivered with adeno-associated viral (AAV) vectors can confer protection against viral challenge in humanized mice. Furthermore, we provide evidence that nAbs can abrogate an ongoing HCV infection in primary hepatocyte cultures and in a human liver chimeric mouse model. These results showcase a novel therapeutic approach to interfere with HCV infection exploiting a previously unappreciated need for HCV to continuously infect new hepatocytes in order to sustain chronicity.en_US
dc.language.isoen_USen_US
dc.relation.ispartofScience Translational Medicineen_US
dc.rightsAuthor's manuscripten_US
dc.titleBroadly neutralizing antibodies abrogate established hepatitis C virus infectionen_US
dc.typeJournal Articleen_US
dc.identifier.doidoi:10.1126/scitranslmed.3009512-
dc.date.eissued2014-09-17en_US
dc.identifier.eissn1946-6242-
pu.type.symplectichttp://www.symplectic.co.uk/publications/atom-terms/1.0/journal-articleen_US

Files in This Item:
File Description SizeFormat 
Broadly_neutralizing_antibodies_hepatitis_c_infection.pdf706.67 kBAdobe PDFView/Download


Items in OAR@Princeton are protected by copyright, with all rights reserved, unless otherwise indicated.